Marcy L. Hackbarth

Alemtuzumab is an effective therapy for chronic lymphocytic leukemia with p53 mutations and deletions

Gerard Lozanski, Nyla A. Heerema, Ian W. Flinn et al. · Blood · 2004 · 403 citations · Full text

Interphase cytogenetic abnormalities in chronic lymphocytic leukemia may predict response to rituximab.

John C. Byrd, Lisa Smith, Marcy L. Hackbarth et al. · PubMed · 2003 · 91 citations

Chronic Lymphocytic Leukemia, Mixed-phenotype Acute Leukemia, Genetics +16

Lymphadenopathy, splenomegaly, and altered immunoglobulin production in BCL3 transgenic mice

S. Tiong Ong, Marcy L. Hackbarth, Linda Degenstein et al. · Oncogene · 1998 · 73 citations

Immunogenetics, Autoimmune Disease, Immune Cell Development +9

Large deletions 5′ to the ETO breakpoint are recurrent events in patients with t(8;21) acute myeloid leukemia

Catherine Godon, John H. Proffitt, Nicole Dastugue et al. · Leukemia · 2002 · 22 citations

Hematological Malignancy, Medicine, Acute Myeloid Leukemia +8

CpG-rich sequences close to the site of duplication within the human IGH constant region

Annamma Sadhu, Mei-Ling Shen, Marcy L. Hackbarth et al. · Immunogenetics · 1997 · 11 citations

Allelic Variant, Cpg-rich Sequences, Genetic Disorder +7